Category: Cardiac Rhythm Management
Meta-analyses of Medtronic-sponsored studies show the clinical and economic benefits of its cardiac resynchronization therapy devices.
Medtronic (NYSE:MDT) yesterday touted the results of meta-analyses of a group of company-sponsored studies of its cardiac resynchronization therapy devices, saying the data show the clinical and economic value its CRT portfolio.
A Medtronic study shows hemodialysis patients experience significantly higher-than-expected rates of arrhythmia and that the episodes appeared to coincide with their treatment cycles.
Boston Scientific reveals a trifecta of reimbursement wins for its S-ICD, including a new reimbursement code from the AMA, a 23% increase in the Medicare rate for implantation and an expansion of coverage by private insurer Aetna.
Boston Scientific (NYSE:BSX) yesterday revealed a trifecta of reimbursement wins for its S-ICD subcutaneous defibrillator from the American Medical Assn., Medicare and Aetna.
Medtronic says it won Japanese approval for its Evera MRI SureScan implantable cardiac defibrillator for full-body MRI exams.
Medtronic (NYSE:MDT) said it won approval from Japan's Ministry of Health, Labor and Welfare for its Evera MRI SureScan implantable cardiac defibrillator for use in full-body MRI scans.
Biotronik pays $5 million but admits no liability to settle allegations that it used kickbacks to induce doctors to use its cardiac rhythm management devices.
Federal prosecutors yesterday said Biotronik agreed to pony up $4.9 million, but admitted no wrongdoing, to settle allegations that it ran a kickbacks scheme to induce physicians to use its cardiac rhythm management devices.
The FDA grants an investigational device exemption for an AtriCure study of patients with non-paroxysmal atrial fibrillation.
AtriCure (NSDQ:ATRC) said it won an investigational device exemption from the FDA for a 1st-of-its-kind clinical trial involving patients with non-paroxysmal atrial fibrillation.
Sales of its cardiac rhythm management devices help boost Boston Scientific above expectations for the 3rd quarter.